Last reviewed · How we verify

Carbocaine

Nantes University Hospital · FDA-approved active Small molecule ✓ Verified Jun 2026

Carbocaine is a Small molecule drug developed by Nantes University Hospital. It is currently FDA-approved for Administration of Local Anesthetic Nerve Block, Administration of Regional Anesthesia, Local anesthesia. Also known as: Loco regional Analgesia.

Carbocaine is a local anesthetic of the amide type, used for conditions such as symptomatic irreversible pulpitis, nerve block, and surgery. It is a small molecule with a reasonably rapid onset and medium duration of action.

At a glance

Generic nameCarbocaine
Also known asLoco regional Analgesia
SponsorNantes University Hospital
TargetSodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha
ModalitySmall molecule
Therapeutic areaPain
PhaseFDA-approved

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Carbocaine

What is Carbocaine?

Carbocaine is a Small molecule drug developed by Nantes University Hospital, indicated for Administration of Local Anesthetic Nerve Block, Administration of Regional Anesthesia, Local anesthesia.

What is Carbocaine used for?

Carbocaine is indicated for Administration of Local Anesthetic Nerve Block, Administration of Regional Anesthesia, Local anesthesia, Local anesthesia, by infiltration.

Who makes Carbocaine?

Carbocaine is developed and marketed by Nantes University Hospital (see full Nantes University Hospital pipeline at /company/nantes-university-hospital).

Is Carbocaine also known as anything else?

Carbocaine is also known as Loco regional Analgesia.

What development phase is Carbocaine in?

Carbocaine is FDA-approved (marketed).

What are the side effects of Carbocaine?

Common side effects of Carbocaine include Respiratory arrest, Convulsions, Unconsciousness, Drowsiness, Cardiovascular catastrophe, Seizure.

What does Carbocaine target?

Carbocaine targets Sodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing